Bioengineering human stem cell-derived beta cell organoids to monitor cell health in real time and improve therapeutic outcomes in patients
Grant Award Details
Grant Type:
Grant Number:
DISC2-13498
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$1,198,550
Status:
Active
Grant Application Details
Application Title:
Bioengineering human stem cell-derived beta cell organoids to monitor cell health in real time and improve therapeutic outcomes in patients
Public Abstract:
Research Objective
We will generate nanoprobe-containing stem cell-derived human beta cells that can be monitored in real time in response to inflammatory stress upon transplantation in patients with type 1 diabetes.
Impact
Our product will replace donor islets for cell replacement therapy in patients with type 1 diabetes, and will provide a readout of cell survival and an opportunity for therapeutic intervention.
Major Proposed Activities
We will generate nanoprobe-containing stem cell-derived human beta cells that can be monitored in real time in response to inflammatory stress upon transplantation in patients with type 1 diabetes.
Impact
Our product will replace donor islets for cell replacement therapy in patients with type 1 diabetes, and will provide a readout of cell survival and an opportunity for therapeutic intervention.
Major Proposed Activities
- Test insulin-producing cell organoids with nanosensors to secrete insulin in response to elevated glucose and emit a signal in real time, and test similar activities in animal models of diabetes.
- Test the ability of insulin-producing cell organoids with nanosensors to emit a measurable signal in response to increased inflammation in vitro and after transplantation in small animal models
Statement of Benefit to California:
The American Diabetes Association states that California, with the highest number of patients with diabetes in the country, also has the highest cost at $39.47 billion. A large proportion of these patients are insulin-dependent and are potential candidates for islet replacement therapy. Developing technologies that can improve transplantation outcomes in patients directly affects long-term quality of life. All Minutia staff are CA residents, with a long history of collaboration with UCSF.